# Clairity, Inc.

> Clairity is a Boston-based healthtech company that built Clairity Breast, the first FDA-authorized AI platform that predicts a woman's five-year risk of breast cancer directly from a routine screening mammogram. Founded by Harvard radiologist Dr. Connie Lehman, the company turns images already sitting in the medical record into a forward-looking risk score, aiming to move breast care from late-stage detection toward early, equitable prevention.

- **Founded:** 2020
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Dr. Connie Lehman (Founder & Chief Science Officer (formerly CEO))
- **Team size:** ~16 employees
- **Products:** Clairity Breast, Clairity Breast 3D, Clairity Heart
- **Notable:** First FDA de novo authorization for an image-based breast cancer risk prediction AI (May 2025)., Founder Dr. Connie Lehman named to TIME's 2026 TIME100 Health List., Model trained on 400,000+ mammograms and validated on ~77,000 additional exams across a diverse population.

## Products & services

- **Clairity Breast** — FDA de novo-authorized, image-based AI that predicts a woman's five-year risk of developing breast cancer using only a standard 2D screening mammogram. Trained on 400,000+ mammograms with five-year follow-up and validated on a diverse population.
- **Clairity Breast 3D** — In-development extension of the risk model to 3D tomosynthesis (DBT) mammography exams.
- **Clairity Heart** — In-development AI that predicts cardiovascular risk from the same routine mammogram image, extending the platform beyond cancer.

## Achievements

- First FDA de novo authorization for an image-based breast cancer risk prediction AI (May 2025).
- Founder Dr. Connie Lehman named to TIME's 2026 TIME100 Health List.
- Model trained on 400,000+ mammograms and validated on ~77,000 additional exams across a diverse population.
- $43M Series B closed November 2025.
- First clinical deployment at Beth Israel Deaconess (Feb 2026).

## Latest updates

- **2026-02** — Beth Israel Deaconess Medical Center begins clinical use of Clairity Breast at its Chestnut Hill clinic.
- **2026-02** — Dr. Connie Lehman named to TIME100 Health 2026 list.
- **2025-11** — Closed $43M Series B led by ACE Global Equity and Santé Ventures.
- **2025-05** — Received FDA de novo authorization for Clairity Breast.

## Links

- Website: https://clairity.com
- LinkedIn: https://www.linkedin.com/company/clairity-inc

---

Profile page: https://yespress.io/clairity-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-07